New Online Casino UK – How Tea Spins is Revolutionising the UK Casino and Slots Scene
New York City, NY, June 07, 2025 (GLOBE NEWSWIRE) -- Tea Spins…
James E. Malackowski Recognized with the Highest Honor in Intellectual Property Licensing
The Licensing Executives Society International presents a Gold Medal to Ocean Tomo…
Seven HKTDC Mega Events Showcase Asias Creative Hub
HONG KONG--(BUSINESS WIRE)--The Hong Kong Trade Development Council (HKTDC) is hosting seven…
Avicanna Announces Receipt of Management Cease Trade Order and Provides Bi-Weekly Status Update
April 07, 2025 16:45 ET | Source: Avicanna Inc. Auditor Licensing &…
OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update…
Computer Modelling Group Announces Third Quarter Results and Quarterly Dividend
CALGARY, Alberta, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Computer Modelling Group Ltd.…
Comanche Biopharma Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway (ILAP) Steering Group for CBP-4888, an Investigational siRNA Drug Candidate for the Treatment of sFlt1-mediated Preterm Preeclampsia
January 30, 2025 05:00 ET | Source: Comanche Biopharma ILAP aims to…
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor – licenced to Norgine for commercialisation in Europe.
LONDON, Jan. 24, 2025 /PRNewswire/ -- Following the licensing agreement with X4…
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor – licenced to Norgine for commercialisation in Europe.
LONDON, Jan. 24, 2025 /PRNewswire/ -- Following the licensing agreement with X4…
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor – licenced to Norgine for commercialisation in Europe.
LONDON, Jan. 24, 2025 /PRNewswire/ -- Following the licensing agreement with X4…